Company Description
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally.
The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems.
The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs.
It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands.
Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
| Country | United States |
| Founded | 1901 |
| IPO Date | Dec 7, 2000 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 391 |
| CEO | James W. Green |
Contact Details
Address: 84 October Hill Rd Holliston, Massachusetts 01746 United States | |
| Phone | (508) 893-8999 |
| Website | harvardbioscience.com |
Stock Details
| Ticker Symbol | HBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001123494 |
| CUSIP Number | 416906105 |
| ISIN Number | US4169061052 |
| Employer ID | 04-3306140 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| James W. Green | President, Chief Executive Officer and Chairman |
| David Balcom | Senior Vice President of Operations |
| John J. Fry | Chief Legal Counsel and Corporation Secretary |
| Ryan Wallace | Senior Vice President of Global Sales |
| Lori Packer | Vice President of Global People Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 3, 2024 | ARS | Filing |
| Apr 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 3, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 7, 2024 | 10-K | Annual Report |
| Mar 7, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |